Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Group 1 - Spyre Therapeutics, Inc. has been added to the Nasdaq Biotechnology Index, effective December 23, 2024 [1] - The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities listed on The Nasdaq Stock Market, with specific eligibility requirements [2] - Spyre Therapeutics focuses on developing next-generation products for Inflammatory Bowel Disease (IBD) using advanced antibody engineering and precision medicine [4] Group 2 - The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 [4]